Novo Nordisk’s Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged ≥2 years

 Novo Nordisk’s Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged ≥2 years

Novo Nordisk’s Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged ≥2 years

Shots:

  • Novo Nordisk’s Tresiba has received an approval for indication expansion by Health Canada for the treatment of pediatric patients (>2 years of age) with Type 1 diabetes
  • The expanded indication follows its last approval in Canada on Aug 2017 for the treatment of adults with Type 1 and Type 2 diabetes
  • Tresiba (insulin degludec injection) is a once-daily, ultra-long-acting basal insulin and is available as FlexTouch prefilled, disposable pen for injecting insulin

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Medical Xpress

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post